Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Respiratory

Set Alert for Respiratory

Aridis' Monoclonal Antibody Rouses Analyst Optimism Despite Pneumonia Phase III Miss

The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.

Clinical Trials Infectious Diseases

Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market

Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.

Infectious Diseases Respiratory

Airsupra Could Help Revive AstraZeneca's Respiratory Fortunes

The US Food and Drug Administration has approved AstraZeneca and Avillion’s respiratory drug Airsupra, making it the only rescue medication cleared for as-needed use to reduce risk of asthma exacerbations.

Respiratory Approvals

Chiesi Expands Its Rare Disease Reach With $1.48bn Amryt Buyout

The privately owned company currently earns most of its revenues in respiratory medicine in Europe, but has set its sights on expanding in rare diseases and the US market.

Companies M & A

Verona Emerges Victorious From Second COPD Trial

After once again showing significant improvements in lung function and a 36% reduction in rate of exacerbations over 24 weeks, Verona is confident that its dual PDE3/4 inhibitor will change the treatment paradigm for COPD.

Respiratory Clinical Trials

Pulmocide Grows Cash Pile For Promising Antifungal

The UK firm has announced an extension of its series C financing which means it has raised just shy of $150m in the last 18 months to fund clinical development, manufacturing scale-up and preparations for the potential commercialization of opelconazole.

Financing Respiratory

C4XD Inks Third Major Deal, This Time With AZ For Oral COPD Drug

The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships. 

Deals Companies

GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion

GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.

Commercial Companies

Flush With CF Success, Vertex Prepares Next-Gen Pipeline For Busy 2023

Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.

Sales & Earnings Commercial

AstraZeneca’s Fasenra Future Weakened By Pivotal Eosinophilic Esophagitis Trial Flop

The major’s monoclonal antibody drug missed one of two primary endpoints in a late-stage eosinophilic esophagitis trial in the second setback this year to plans for label expansion beyond the asthma maintenance setting.

Clinical Trials Respiratory

Verona Boosts Funds And Becomes Potential Takeover Target

The UK biotech is in a strong spot after extending its cash runway to prepare for the launch of ensifentrine, which analysts believe could become a pipeline-in-a-molecule for respiratory diseases.

Business Strategies Clinical Trials

Tezspire All Set To Tackle Big Biologic Rivals In Severe Asthma

With a European approval in the bag for Tezspire, AstraZeneca is looking for quick and successful launches of the severe asthma drug so it can mount a challenge to the other biologics in the space, notably Sanofi and Regeneron’s Dupixent.

Approvals Respiratory
See All
UsernamePublicRestriction

Register